Abstract Library

#2802 EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI)

Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Coriat R

Authors: Cadiot G, Coriat R, Raverot G, Nguyen Tan Hon T, Raingeard I,

Keywords: Octreotide LAR, NET, Acromegaly, Nurse,

#2126 Histone Replacement in Cancer: Dissecting the Role of H3.3 Chaperones in Pancreatic Tumorigenesis

Introduction: Cancer driver mutations affecting the histone H3.3 chromatin remodellers ATRX and DAXX were recently discovered in 43% of sporadic pancreatic neuroendocrine tumours (PNET). Progressive age-dependent replacement of canonical H3.1/2 with H3.3 is crucial for maintaining genome integrity through expression of repressive markers at heterochromatic sites, where loading is mediated by ATRX and DAXX. Loss of H3.3 chaperones in PNET is associated with activation of ALT, a telomere maintenance mechanism, eventually leading to chromosome instability. It has been suggested that ATRX/DAXX expression is necessary for repressing ALT, but mechanistic details of this interaction are not fully understood.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sposito T

Authors: Sposito T, C Nguyen Tu M, Thirlwell C, Salomoni P,

Keywords: PNET, mouse model, epigenetic,

#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials

Introduction: LAN provide antitumor effects and symptom control in NET pts.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Buil-Bruna N, Jesús Garrido M, Dehez M, Manon A, Nguyen T,

Keywords: PK, dosing,

#792 Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors

Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Strosberg J

Authors: Cives M, Kunz P, Nguyen P, Jump H, Vilay K,

Keywords: NET, pasireotide, first-line,